MHRA Announces Major Regulatory Reforms to Strengthen Access to World Class Medical Devices in the United Kingdom

The Medicines and Healthcare products Regulatory Agency has announced a significant set of reforms designed to give patients faster access to trusted medical technologies and support stronger economic growth in the United Kingdom medtech sector.

The proposals introduce new international reliance routes that will allow medical devices approved by trusted regulators in Australia, Canada and the United States to enter the Great Britain market through a smoother and more efficient process. This approach is expected to reduce regulatory duplication, shorten approval timelines and encourage greater innovation across the healthcare technology landscape.

The MHRA has also proposed removing the requirement for a physical United Kingdom Conformity Assessment mark once unique device identification systems are fully in place. This measure is intended to lower costs for manufacturers and create a clearer and more flexible regulatory environment.

Later this year, the agency will open a consultation exploring continued acceptance of CE marked devices within Great Britain. This would provide further stability for manufacturers and help maintain a strong supply of safe and effective medical technologies across the country.

The MHRA explained that these reforms are focused on improving patient safety, encouraging faster access to proven technologies and supporting the United Kingdom as a competitive and attractive destination for medical device development and market entry.

What this means for global exhibitors exploring EBME Expo 2026

The regulatory changes announced by the MHRA create new advantages for international companies considering participation in EBME Expo in 2026.

These proposals mean global exhibitors will benefit from the following opportunities:

• Easier and faster entry into the United Kingdom market. Devices already approved by respected regulators will face fewer barriers, making the United Kingdom a more accessible destination for product launches and partnership discussions.
• Reduced administrative and financial pressure. The removal of a physical United Kingdom Conformity Assessment mark and continued acceptance of CE marked devices will simplify compliance for manufacturers from Europe, North America, Asia and other regions.
• A more competitive environment for showcasing innovation. With the United Kingdom focusing on international alignment and streamlined approval pathways, exhibitors can introduce new technologies to buyers and clinical engineering professionals with greater confidence.
• A stronger market for commercial partnerships. Distributors, procurement teams and service providers will be better positioned to consider new brands and technologies, widening the opportunity for exhibitors to build both commercial and clinical relationships.
• Increased demand from hospitals and health services. A more flexible regulatory system supports faster adoption of new devices, which means exhibitors can present solutions that are more likely to reach end users without long delays.

EBME Expo 2026 will therefore take place at a time when the United Kingdom is actively encouraging innovation, international collaboration and technological advancement. Global manufacturers and suppliers will find a more welcoming and more accessible market environment, making the event an attractive platform for market entry, brand expansion and strategic partnerships.

Book a stand